KINEVANT SCIENCES
KINEVANT SCIENCES logo

Kinevant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases. The company takes a patient-first approach to drug development, advancing candidates with the potential to resolve the underlying disease and create life-changing benefit for patients. Kinevant is initially focusing on sarcoidosis with an anti-GM-CSF monoclonal antibody, namilumab, currently being evaluated in the Phase 2 RESOLVE-Lung study in patients with pulmonary sarcoidosis.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.